Safety profile of ocriplasmin for the pharmacologic treatment of symptomatic vitreomacular adhesion/traction.

@article{Kaiser2015SafetyPO,
  title={Safety profile of ocriplasmin for the pharmacologic treatment of symptomatic vitreomacular adhesion/traction.},
  author={Peter K. Kaiser and Anselm Kampik and Baruch D. Kuppermann and Aniz Girach and Stanislao Rizzo and Robert C. Sergott},
  journal={Retina},
  year={2015},
  volume={35 6},
  pages={1111-27}
}
PURPOSE To report the safety of intravitreal ocriplasmin injection based on 2 Phase 3 clinical trials in patients with symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with full-thickness macular holes. METHODS Safety analyses were based on 2 completed Phase 3 studies assessing intravitreal ocriplasmin injection. Adverse events (AEs), serious AEs, and suspected adverse drug reactions are reported. The authors also report AEs of special interest from 8 other… CONTINUE READING
Highly Cited
This paper has 137 citations. REVIEW CITATIONS
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

137 Citations

050100150201620172018
Citations per Year
Semantic Scholar estimates that this publication has 137 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
Showing 1-10 of 54 references

Similar Papers

Loading similar papers…